Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
20
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| de Garidel Marc | Chief Executive Officer | 6 | $200.0K | $0 | 2023-02-24 |
| Pearce Catherine | Chief Operating Officer | 13 | $36.0K | $0 | 2023-02-24 |
| Allison David D. | Director | 10 | $0 | $0 | 2023-02-24 |
| Freeman Mason | EVP Clinical Development | 10 | $41.6K | $91 | 2023-02-24 |
| Lee June | Director | 2 | $0 | $0 | 2023-02-24 |
| Kalb Michael Wayne | EVP & Chief Financial Officer | 5 | $0 | $0 | 2023-02-24 |
| Schwab Andrew J. | 10% Owner | 3 | $0 | $0 | 2023-02-24 |
| Ignelzi Troy A. | Director | 2 | $0 | $0 | 2023-02-24 |
| HEALY JAMES | Director, 10% Owner | 12 | $20.38M | $85.9K | 2023-02-24 |
| THERO JOHN F | Director | 2 | $0 | $0 | 2023-02-24 |
| 5AM Partners VI, LLC | 10% Owner | 2 | $18.00M | $0 | 2022-08-15 |
| Sofinnova Partners SAS | 10% Owner | 1 | $4.00M | $0 | 2022-08-15 |
| Sofinnova Management X, L.L.C. | 10% Owner | 1 | $15.00M | $0 | 2022-08-11 |
| GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10% Owner | 4 | $29.69M | $0 | 2022-08-11 |
| GAP COINVESTMENTS III, LLC | 10% Owner | 4 | $29.69M | $0 | 2022-08-11 |
| CinRx Pharma, LLC | 10% Owner | 3 | $0 | $0 | 2022-01-11 |
| Sofinnova Capital IX | 10% Owner | 4 | $3.52M | $0 | 2022-01-11 |
| Coelho Mary Theresa | EVP CFO & Chief BD Officer | 1 | $1.6K | $0 | 2022-01-11 |
| Sofinnova Venture Partners X, L.P. | 10% Owner | 4 | $5.20M | $0 | 2022-01-11 |
| PARMAR KUSH | 10% Owner | 7 | $7.52M | $0 | 2022-01-11 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| de Garidel Marc | Chief Executive Officer | D To issuer deriv | 2023-02-24 | 2023-02-24 | 726,483 | — | $0 | 0 | SEC↗ |
| de Garidel Marc | Chief Executive Officer | D To issuer deriv | 2023-02-24 | 2023-02-24 | 601,901 | — | $0 | 0 | SEC↗ |
| THERO JOHN F | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 36,324 | — | $0 | 0 | SEC↗ |
| THERO JOHN F | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 58,823 | — | $0 | 0 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | D To issuer deriv | 2023-02-24 | 2023-02-24 | 13,236 | — | $0 | 0 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | D To issuer deriv | 2023-02-24 | 2023-02-24 | 110,136 | — | $0 | 0 | SEC↗ |
| Lee June | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 47,954 | — | $0 | 0 | SEC↗ |
| Kalb Michael Wayne | EVP & Chief Financial Office | D To issuer deriv | 2023-02-24 | 2023-02-24 | 77,615 | — | $0 | 0 | SEC↗ |
| Ignelzi Troy A. | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 58,823 | — | $0 | 0 | SEC↗ |
| Ignelzi Troy A. | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 36,324 | — | $0 | 0 | SEC↗ |
| Allison David D. | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 1,499 | — | $0 | 0 | SEC↗ |
| Allison David D. | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 29,411 | — | $0 | 0 | SEC↗ |
| Allison David D. | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 1,038 | — | $0 | 0 | SEC↗ |
| Allison David D. | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 881 | — | $0 | 0 | SEC↗ |
| Allison David D. | Director | D To issuer deriv | 2023-02-24 | 2023-02-24 | 524 | — | $0 | 0 | SEC↗ |
| Freeman Mason | Chief Medical Officer | D To issuer deriv | 2023-02-24 | 2023-02-27 | 120,380 | — | $0 | 0 | SEC↗ |
| Freeman Mason | Chief Medical Officer | D To issuer deriv | 2023-02-24 | 2023-02-27 | 30,178 | — | $0 | 0 | SEC↗ |
| Freeman Mason | Chief Medical Officer | D To issuer deriv | 2023-02-24 | 2023-02-27 | 145,296 | — | $0 | 0 | SEC↗ |
| de Garidel Marc | Chief Executive Officer | U Tender | 2023-02-24 | 2023-02-24 | 12,500 | — | $0 | 200,000 | SEC↗ |
| de Garidel Marc | Chief Executive Officer | D To issuer | 2023-02-24 | 2023-02-24 | 200,000 | — | $0 | 0 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | D To issuer | 2023-02-24 | 2023-02-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | U Tender | 2023-02-24 | 2023-02-24 | 140,149 | — | $0 | 15,000 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | U Tender | 2023-02-24 | 2023-02-24 | 1,500 | — | $0 | 0 | SEC↗ |
| Kalb Michael Wayne | EVP & Chief Financial Office | D To issuer | 2023-02-24 | 2023-02-24 | 202,437 | — | $0 | 0 | SEC↗ |
| Freeman Mason | Chief Medical Officer | D To issuer | 2023-02-24 | 2023-02-27 | 40,000 | — | $0 | 0 | SEC↗ |
| Freeman Mason | Chief Medical Officer | U Tender | 2023-02-24 | 2023-02-27 | 100 | — | $0 | 0 | SEC↗ |
| Freeman Mason | Chief Medical Officer | U Tender | 2023-02-24 | 2023-02-27 | 2,494 | — | $0 | 40,000 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | U Tender | 2023-02-24 | 2023-02-27 | 9,803 | — | $0 | 19,608 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | D To issuer | 2023-02-24 | 2023-02-27 | 19,608 | — | $0 | 0 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | U Tender | 2023-02-24 | 2023-02-27 | 6,073,949 | — | $0 | 0 | SEC↗ |
| Schwab Andrew J. | 10% Owner | U Tender | 2023-02-24 | 2023-02-28 | 496,323 | — | $0 | 0 | SEC↗ |
| Schwab Andrew J. | 10% Owner | U Tender | 2023-02-24 | 2023-02-28 | 3,953,990 | — | $0 | 0 | SEC↗ |
| Schwab Andrew J. | 10% Owner | U Tender | 2023-02-24 | 2023-02-28 | 487,333 | — | $0 | 0 | SEC↗ |
| Freeman Mason | Chief Medical Officer | A Award | 2023-01-26 | 2023-01-30 | 40,000 | — | $0 | 42,500 | SEC↗ |
| Kalb Michael Wayne | EVP & Chief Financial Office | A Award | 2023-01-26 | 2023-01-30 | 177,000 | — | $0 | 202,437 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | A Award | 2023-01-26 | 2023-01-30 | 15,000 | — | $0 | 155,149 | SEC↗ |
| de Garidel Marc | Chief Executive Officer | A Award | 2023-01-26 | 2023-01-30 | 200,000 | — | $0 | 212,500 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | M Exercise deriv | 2023-01-11 | 2023-01-19 | 13,235 | — | $0 | 13,236 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | M Exercise | 2023-01-11 | 2023-01-19 | 13,235 | — | $0 | 144,146 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | F Tax w/h | 2023-01-11 | 2023-01-19 | 3,997 | $28.75 | $114.9K | 140,149 | SEC↗ |
| Allison David D. | Director | A Award deriv | 2023-01-06 | 2023-01-10 | 1,499 | $8.34 | $12.5K | 1,499 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | S Sale | 2022-11-28 | 2023-02-27 | 6,000 | $14.32 | $85.9K | 0 | SEC↗ |
| Kalb Michael Wayne | EVP & Chief Financial Office | A Award deriv | 2022-11-04 | 2022-11-08 | 77,615 | — | $0 | 77,615 | SEC↗ |
| Kalb Michael Wayne | EVP & Chief Financial Office | A Award | 2022-11-04 | 2022-11-08 | 25,437 | — | $0 | 25,437 | SEC↗ |
| Allison David D. | Director | A Award deriv | 2022-10-07 | 2022-10-12 | 524 | $23.85 | $12.5K | 524 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | P Buy | 2022-08-15 | 2022-08-17 | 133,333 | $30.00 | $4.00M | 4,220,979 | SEC↗ |
| 5AM Partners VI, LLC | 10% Owner | P Buy | 2022-08-15 | 2022-08-17 | 112,667 | $30.00 | $3.38M | 3,953,990 | SEC↗ |
| 5AM Partners VI, LLC | 10% Owner | P Buy | 2022-08-15 | 2022-08-17 | 487,333 | $30.00 | $14.62M | 487,333 | SEC↗ |
| GAP COINVESTMENTS III, LLC | 10% Owner | P Buy | 2022-08-11 | 2022-08-15 | 83,000 | $30.00 | $2.49M | 4,209,470 | SEC↗ |
| GENERAL ATLANTIC GENPAR (BERMU | 10% Owner | P Buy | 2022-08-11 | 2022-08-15 | 83,000 | $30.00 | $2.49M | 4,209,470 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | P Buy | 2022-08-11 | 2022-08-15 | 6,000 | $30.00 | $180.0K | 6,000 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | P Buy | 2022-08-11 | 2022-08-15 | 500,000 | $30.00 | $15.00M | 6,073,949 | SEC↗ |
| Sofinnova Management X, L.L.C. | 10% Owner | P Buy | 2022-08-11 | 2022-08-15 | 500,000 | $30.00 | $15.00M | 6,073,949 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | M Exercise deriv | 2022-08-05 | 2022-08-08 | 29,411 | — | $0 | 0 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | M Exercise | 2022-08-05 | 2022-08-08 | 29,411 | $13.60 | $400.0K | 29,411 | SEC↗ |
| Allison David D. | Director | A Award deriv | 2022-07-08 | 2022-07-20 | 881 | $14.19 | $12.5K | 881 | SEC↗ |
| Freeman Mason | Chief Medical Officer | S Sale | 2022-06-10 | 2023-02-27 | 6 | $15.21 | $91 | 2,494 | SEC↗ |
| Allison David D. | Director | A Award deriv | 2022-04-08 | 2022-07-20 | 1,038 | $12.04 | $12.5K | 1,038 | SEC↗ |
| Allison David D. | Director | A Award deriv | 2022-04-08 | 2022-05-11 | 1,038 | — | $0 | 1,038 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | A Award deriv | 2022-01-12 | 2022-01-13 | 26,471 | — | $0 | 26,471 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 4,275,000 | — | $0 | 0 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 13,571,428 | — | $0 | 0 | SEC↗ |
| Sofinnova Capital IX | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 9,999,999 | — | $0 | 0 | SEC↗ |
| Sofinnova Capital IX | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 3,150,000 | — | $0 | 0 | SEC↗ |
| Sofinnova Venture Partners X, | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 13,571,428 | — | $0 | 0 | SEC↗ |
| Sofinnova Venture Partners X, | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 4,275,000 | — | $0 | 0 | SEC↗ |
| CinRx Pharma, LLC | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 2,142,856 | — | $0 | 0 | SEC↗ |
| CinRx Pharma, LLC | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 2,013,749 | — | $0 | 0 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 625,000 | — | $0 | 0 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 2,525,000 | — | $0 | 0 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 9,999,999 | — | $0 | 0 | SEC↗ |
| GAP COINVESTMENTS III, LLC | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 8,250,000 | — | $0 | 0 | SEC↗ |
| GENERAL ATLANTIC GENPAR (BERMU | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-13 | 8,250,000 | — | $0 | 0 | SEC↗ |
| Coelho Mary Theresa | EVP CFO & Chief BD Officer | P Buy | 2022-01-11 | 2022-01-13 | 100 | $16.00 | $1.6K | 100 | SEC↗ |
| de Garidel Marc | Chief Executive Officer | P Buy | 2022-01-11 | 2022-01-13 | 12,500 | $16.00 | $200.0K | 12,500 | SEC↗ |
| Freeman Mason | EVP Clinical Development | P Buy | 2022-01-11 | 2022-01-13 | 2,500 | $16.00 | $40.0K | 2,500 | SEC↗ |
| Freeman Mason | EVP Clinical Development | P Buy | 2022-01-11 | 2022-01-13 | 100 | $16.00 | $1.6K | 100 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | P Buy | 2022-01-11 | 2022-01-13 | 750 | $16.00 | $12.0K | 130,911 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | P Buy | 2022-01-11 | 2022-01-13 | 1,500 | $16.00 | $24.0K | 1,500 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | C Conversion | 2022-01-11 | 2022-01-13 | 5,248,949 | — | $0 | 5,248,949 | SEC↗ |
| HEALY JAMES | Director, 10% Owner | P Buy | 2022-01-11 | 2022-01-13 | 325,000 | $16.00 | $5.20M | 5,573,949 | SEC↗ |
| Sofinnova Capital IX | 10% Owner | P Buy | 2022-01-11 | 2022-01-13 | 220,000 | $16.00 | $3.52M | 4,087,646 | SEC↗ |
| Sofinnova Capital IX | 10% Owner | C Conversion | 2022-01-11 | 2022-01-13 | 3,867,646 | — | $0 | 3,867,646 | SEC↗ |
| Sofinnova Venture Partners X, | 10% Owner | C Conversion | 2022-01-11 | 2022-01-13 | 5,248,949 | — | $0 | 5,248,949 | SEC↗ |
| Sofinnova Venture Partners X, | 10% Owner | P Buy | 2022-01-11 | 2022-01-13 | 325,000 | $16.00 | $5.20M | 5,573,949 | SEC↗ |
| CinRx Pharma, LLC | 10% Owner | C Conversion | 2022-01-11 | 2022-01-13 | 1,222,530 | — | $0 | 3,630,103 | SEC↗ |
| PARMAR KUSH | 10% Owner | P Buy | 2022-01-11 | 2022-01-13 | 312,500 | $16.00 | $5.00M | 496,323 | SEC↗ |
| PARMAR KUSH | 10% Owner | P Buy | 2022-01-11 | 2022-01-13 | 157,500 | $16.00 | $2.52M | 3,841,323 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion | 2022-01-11 | 2022-01-13 | 183,823 | — | $0 | 183,823 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion | 2022-01-11 | 2022-01-13 | 3,683,823 | — | $0 | 3,683,823 | SEC↗ |
| GAP COINVESTMENTS III, LLC | 10% Owner | C Conversion | 2022-01-11 | 2022-01-13 | 2,426,470 | — | $0 | 2,426,470 | SEC↗ |
| GAP COINVESTMENTS III, LLC | 10% Owner | P Buy | 2022-01-11 | 2022-01-13 | 1,700,000 | $16.00 | $27.20M | 4,126,470 | SEC↗ |
| GENERAL ATLANTIC GENPAR (BERMU | 10% Owner | P Buy | 2022-01-11 | 2022-01-13 | 1,700,000 | $16.00 | $27.20M | 4,126,470 | SEC↗ |
| GENERAL ATLANTIC GENPAR (BERMU | 10% Owner | C Conversion | 2022-01-11 | 2022-01-13 | 2,426,470 | — | $0 | 2,426,470 | SEC↗ |
| Lee June | Director | A Award deriv | 2022-01-06 | 2022-01-10 | 47,954 | — | $0 | 47,954 | SEC↗ |
| Pearce Catherine | Chief Operating Officer | A Award deriv | 2022-01-06 | 2022-01-10 | 26,471 | — | $0 | 26,471 | SEC↗ |